Latest

Photos from TAC demonstration outside SCA

Yesterday, during the hearing on the Docetaxel patent infringement case, TAC members demonstrated outside of the Supreme Court of Appeal. The hearing has now concluded and we are awaiting a judgement from the court. Once a judgement is received, we will circulate it widely.  

READ MORE

Mail&Guardian discuss the Docetaxel patent challenge

Yesterday the Mail&Guardian published an article on the Docetaxel case. “The TAC and Section 27 have joined the fray in a face-off between Aventis Pharma and Cipla Life Sciences in a patent war over cancer drug Docetaxel.” The full article can be found here  

READ MORE

Patents vs Access to drugs

This article by Anso Thom was published on 14.05.2012. The original can be found at http://health-e.org.za/news/article.php?uid=20033533 OPINION: Lifesaving drugs under disputed patents couldbecome more easily available in future depending on the outcome of a case before the Supreme Court of Appeal in Bloemfontein on Tuesday.

READ MORE

TAC to argue that the public interest and the right to access to health care services must be considered in patent dispute in the Supreme Court of Appeal

On 15 May 2012, the Supreme Court of Appeal will hear arguments in the case of Aventis Pharma SA and Others v Cipla Life Sciences and Others in the patent dispute over the cancer medicine Docetaxel (brand name Taxotere).  The Treatment Action Campaign (TAC) has been admitted to the proceedings as amicus curiae (friend of […]

READ MORE

Update on docetaxel patent infringement case

TAC has been admitted as Amicus Curiae in the docetaxel patent challenge between Cipla and Aventis. The case will be heard in the Supreme Court of Appeal in Bloemfontein, Free State on 15 May 2012.  Today SECTION27 filed the Heads of Argument on behalf of TAC which can be accessed here

READ MORE